Using a cohort of patients whose tumors underwent comprehensive genomic and targeted immune transcriptomic analysis, we characterized the immune gene expression profile of EGFR mutant and Nrf2 altered NSCLC tumor samples. This evidence concerns the gene EGFR and neoplasm.